New hope drug enters human testing for Tough-to-Treat cancers

NCT ID NCT06120075

Ongoing Disease control Sponsor: Arcus Biosciences, Inc. Source: ClinicalTrials.gov ↗

Summary

This is an early-stage safety study for a new drug called AB801, given alone or with other treatments, for people with advanced cancers that have stopped responding to available therapies. The main goal is to find a safe dose and understand the drug's side effects in about 91 participants with specific advanced solid tumors, like lung and colorectal cancer. It's a first step to see if the drug is safe enough for larger studies that would test how well it works.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Emory University

Atlanta, Georgia, 30322, United States
Georgetown

Washington D.C., District of Columbia, 20007, United States
Icahn School of Medicine at Mount Sinai/ The Tisch Cancer Center

New York, New York, 10128, United States
Mary Crowley

Dallas, Texas, 75230, United States
Next Oncology Virginia

Fairfax, Virginia, 22031, United States
START - South Texas Accelerated Research Therapeutics, LLC.

San Antonio, Texas, 78229, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
START Mountain Region

West Valley City, Utah, 84119, United States
Sarah Cannon Research Institute

Denver, Colorado, 80218, United States
University Of Pennsylvania, Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED CANCER